Discover
TVTX
Travere Therapeutics, Inc.
60.21
4 x 60.25
1 x 62.20
bid
ask
-
0.68
1.12%
16 @ 04:00 PM
60.28 +0.07 (0.12%)
| Ytd | 57.58% | |
| 1y | 248.44% |
60.20
day range
61.97
17.05
52 week range
66.24
| Open | 60.75 | Prev Close | 60.89 | Low | 60.20 | High | 61.97 | Mkt Cap | 5.60B |
| Vol | 1.03M | Avg Vol | 1.94M | EPS | -0.45 | P/E | -133.80 | Forward P/E | 11.17 |
| Beta | 1.04 | Short Ratio | 5.91 | Inst. Own | 110.95% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-04 | 50-d Avg | 54.80 | 200-d Avg | 39.34 | 1yr Est | 71.71 |
| Income Statement | |||
| Total Revenue | 169.58M | ||
| Revenues (USD) | 169.58M | ||
| Cost of Revenue | 2.17M | ||
| Gross Profit | 167.41M | ||
| Operating Expenses | 163.46M | ||
| Research and Development Expense | 60.28M | ||
| Selling, General and Administrative Expense | 96.11M | ||
| Operating Income | 3.95M | ||
| Interest Expense | 2.13M | ||
| Income Tax Expense | -204.00K | ||
| Net Income | -34.80M | ||
| Net Income Common Stock | -34.80M | ||
| Net Income Common Stock (USD) | -34.80M | ||
| Consolidated Income | -34.80M | ||
| Earnings per Basic Share | -0.37 | ||
| Earnings per Basic Share (USD) | -0.37 | ||
| Earnings per Diluted Share | -0.37 | ||
| Earning Before Interest & Taxes (EBIT) | -32.87M | ||
| Earning Before Interest & Taxes (USD) | -32.87M | ||
| Weighted Average Shares | 93.48M | ||
| Weighted Average Shares Diluted | 93.48M | ||
| Balance Sheet | |||
| Cash and Equivalents | 117.74M | ||
| Cash and Equivalents (USD) | 117.74M | ||
| Investments | 371.44M | ||
| Investments Current | 371.44M | ||
| Trade and Non-Trade Receivables | 80.64M | ||
| Current Assets | 615.14M | ||
| Property, Plant & Equipment Net | 11.98M | ||
| Total Assets | 799.36M | ||
| Debt Current | 6.16M | ||
| Total Debt | 616.91M | ||
| Current Liabilities | 152.03M | ||
| Debt Non-Current | 610.74M | ||
| Total Liabilities | 774.84M | ||
| Accumulated Retained Earnings (Deficit) | -1.54B | ||
| Accumulated Other Comprehensive Income | -1.12M | ||
| Shareholders Equity | 24.52M | ||
| Shareholders Equity (USD) | 24.52M | ||
| Assets Non-Current | 184.22M | ||
| Total Debt (USD) | 616.91M | ||
| Goodwill and Intangible Assets | 131.52M | ||
| Inventory | 40.05M | ||
| Liabilities Non-Current | 622.81M | ||
| Trade and Non-Trade Payables | 7.50M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 4.23M | ||
| Net Cash Flow from Financing | 187.52M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 39.37M | ||
| Capital Expenditure | -21.07M | ||
| Issuance (Purchase) of Equity Shares | 30.20M | ||
| Issuance (Repayment) of Debt Securities | 157.85M | ||
| Net Cash Flow from Investing | -206.29M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -185.22M | ||
| Net Cash Flow from Operations | 58.07M | ||
| Effect of Exchange Rate Changes on Cash | 72.00K | ||
| Share Based Compensation | 21.79M | ||